Measurement of Serum Calprotectin in Stable Patients Predicts Exacerbation and Lung Function Decline in Cystic Fibrosis.

Reid PA, McAllister DA, Boyd AC, Innes JA, Porteous D, Greening AP, Gray RD

American Journal of Respiratory and Critical Care Medicine

Am J Respir Crit Care Med. 2015 Jan 15;191(2):233-236.

Contact us about this publication

Print this page

Clinical tests that predict clinical outcomes in cystic fibrosis (CF) such as exacerbation risk and lung function decline are lacking.

Calprotectin (MRP8/14, S100A8/A9) is an abundant neutrophil protein found in bronchoalveolar lavage fluid (1), sputum (2), and serum of patients with CF (3).

We have demonstrated that serum calprotectin changes with treatment of exacerbation, and predicts time to re-exacerbation .

We hypothesized that stable patients with higher serum calprotectin at baseline would exacerbate sooner and have more rapid lung function decline.

Go Back to Publications     View on Pubmed (25590159)    View on Google Scholar